Essentials of Model-informed Drug Development (MIDD) – Top-down vs. Bottom-up Approaches Blog 模型引导的药物开发 (MIDD) 要点—自上而下与自下而上的方法对比 How can the latest modeling and simulation technologies accelerate drug discovery and development? We frequently…Jim Gallagher2021 年 9 月 2 日
Using Simcyp Simulator to Determine DDI Liability of Guanfacine in Children Case Study 使用 Simcyp Simulator 确定 Guanfacine 在儿童中的药物相互作用风险 Guanfacine (Intuniv® XR) extended release (GXR) is an orally administered, selective alpha2A-adrenergic receptor agonist, non-stimulant…Jim Gallagher2021 年 8 月 26 日
Using a PBPK-PD Receptor Occupancy Model to Determine the Optimal Dose of Radiprodil for Neonates Case Study Using a PBPK-PD Receptor Occupancy Model to Determine the Optimal Dose of Radiprodil for Neonates Radiprodil is a selective allosteric modulator of the NR2B N-methyl-D-aspartate receptor GluN2B-NMDA that was being…Jim Gallagher2021 年 8 月 26 日
Bridging Formulations of Quetiapine for Children with Schizophrenia or Bipolar Disorder Case Study Bridging Formulations of Quetiapine for Children with Schizophrenia or Bipolar Disorder Quetiapine is an atypical antipsychotic for treating schizophrenia, bipolar depression, bipolar mania that helps to…Jim Gallagher2021 年 8 月 26 日
Simcyp’s Age-Defining Feature Facilitates Everolimus Dosing in Neonates Case Study Simcyp’s Age-Defining Feature Facilitates Everolimus Dosing in Neonates Everolimus (Afinitor®) was recently approved as adjunctive therapy for tuberous sclerosis complex (TSC)-associated partial seizures…Jim Gallagher2021 年 8 月 26 日
Eliglustat for Gaucher Disease: Quantifying the Impact of Pharmacogenetic Status on DDIs Case Study Eliglustat for Gaucher Disease: Quantifying the Impact of Pharmacogenetic Status on DDIs In 2014, Eliglustat (Cerdelga®) was approved by the FDA as the first long-term treatment for…Jim Gallagher2021 年 8 月 26 日
Using PBPK for Label Recommendations in Rare Disease: Deflazacort for Duchenne Muscular Dystrophy Case Study Using PBPK for Label Recommendations in Rare Disease: Deflazacort for Duchenne Muscular Dystrophy Jim Gallagher2021 年 8 月 20 日
Immunogenicity Prediction and Dose Optimization using Clinically-Validated In Silico Modeling & Simulation White Paper 使用经临床验证的计算机建模和模拟进行免疫原性预测和剂量优化 Jim Gallagher2021 年 8 月 19 日
How New FDA Guidance Project Optimus May Affect Future of Oncology Clinical Trials, Drug Pipeline Article 全新 FDA 指南 Project Optimus 可能如何影响肿瘤学临床试验和药物研究计划的未来 Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the…Jim Gallagher2021 年 8 月 16 日